Literature DB >> 25442003

Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.

Matthieu F Bastide1, Brice de la Crompe1, Evelyne Doudnikoff1, Pierre-Olivier Fernagut1, Christian E Gross2, Nicolas Mallet1, Thomas Boraud1, Erwan Bézard3.   

Abstract

BACKGROUND: A systematic search of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in Parkinson's disease shed light, notably, upon the lateral habenula (LHb), which displayed an overexpression of the ∆FosB, ARC, and Zif268 immediate-early genes only in rats experiencing abnormal involuntary movements (AIMs). We thus hypothesized that LHb might play a role in LID.
METHODS:FosB immunoreactivity, 2-deoxyglucose uptake, and firing activity of LHb were studied in experimental models of Parkinson's disease and LID. ΔFosB-expressing LHb neurons were then targeted using the Daun02-inactivation method. A total of 18 monkeys and 55 rats were used.
RESULTS: LHb was found to be metabolically modified in dyskinetic monkeys and its neuronal firing frequency significantly increased in ON L-DOPA dyskinetic 6-hydroxydopamine-lesioned rats, suggesting that increased LHb neuronal activity in response to L-DOPA is related to AIM manifestation. Therefore, to mechanistically test if LHb neuronal activity might affect AIM severity, following induction of AIMs, 6-hydroxydopamine rats were injected with Daun02 in the LHb previously transfected with ß-galactosidase under control of the FosB promoter. Three days after Daun02 administration, animals were tested daily with L-DOPA to assess LID and L-DOPA-induced rotations. Inactivation of ∆FosB-expressing neurons significantly reduced AIM severity and also increased rotations. Interestingly, the dopaminergic D1 receptor was overexpressed only on the lesioned side of dyskinetic rats in LHb and co-localized with ΔFosB, suggesting a D1 receptor-mediated mechanism supporting the LHb involvement in AIMs.
CONCLUSIONS: This study highlights the role of LHb in LID, offering a new target to innovative treatments of LID.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  2-Deoxyglucose; Daun02; Electrophysiology; Macaque; Parkinson’s disease; Rat

Mesh:

Substances:

Year:  2014        PMID: 25442003     DOI: 10.1016/j.biopsych.2014.08.022

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  5 in total

1.  Granger causality supports abnormal functional connectivity of beta oscillations in the dorsolateral striatum and substantia nigra pars reticulata in hemiparkinsonian rats.

Authors:  Qiang Wang; Min Li; Zhengyuan Xie; Junbin Cai; Nanxiang Li; Hu Xiao; Ning Wang; Jinyan Wang; Fei Luo; Wangming Zhang
Journal:  Exp Brain Res       Date:  2017-08-17       Impact factor: 1.972

2.  Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.

Authors:  Matthieu F Bastide; Christelle Glangetas; Evelyne Doudnikoff; Qin Li; Mathieu Bourdenx; Pierre-Olivier Fernagut; Éric C Dumont; François Georges; Erwan Bézard
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

Review 3.  On the neuronal circuitry mediating L-DOPA-induced dyskinesia.

Authors:  M Angela Cenci; Henrik Jörntell; Per Petersson
Journal:  J Neural Transm (Vienna)       Date:  2018-04-27       Impact factor: 3.575

4.  Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.

Authors:  Elva Fridjonsdottir; Reza Shariatgorji; Anna Nilsson; Theodosia Vallianatou; Luke R Odell; Luke S Schembri; Per Svenningsson; Pierre-Olivier Fernagut; Alan R Crossman; Erwan Bezard; Per E Andrén
Journal:  Sci Adv       Date:  2021-01-06       Impact factor: 14.136

Review 5.  L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning.

Authors:  Abdeslam Chagraoui; Marie Boulain; Laurent Juvin; Youssef Anouar; Grégory Barrière; Philippe De Deurwaerdère
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.